HEALTH TECHNOLOGY VASOPRESSIN SAMBONG 250 MG TABLET VARENICLINE NICOTINE REPLACEMENT THERAPY 2.5% PERITONEAL DIALYSIS SOLUTION 0.1% SODIUM HYALURONATE (15 ML)
PROPONENT DOH Disease Prevention and Control Bureau Philippine Institute of Traditional and Alternative Health Care (PITAHC) DPCB - Lifestyle-Related Diseases Division DPCB - Lifestyle-Related Diseases Division Philippine General Hospital, National Kidney and Transplant Institute Asian Eyes Optical
TOPIC NOMINATION
APPRAISAL AND RECOMMENDATION
APPEALS ON PRELIMINARY HTAC RECOMMENDATION
FINAL RECOMMENDATION 28 February 2022 14 January 2022 17 May 2021 17 May 2021 17 February 2021 10 March 2021
DECISION OF THE SECRETARY OF HEALTH 02 March 2022 14 January 2022 17 May 2021 17 May 2021 19 February 2021 10 March 2021
DISSEMINATION Link to HTAC RecommendationLink to HTAC RecommendationLink to issuanceLink to issuanceLink to IssuanceLink to Issuance

HEALTH TECHNOLOGY ORAL PRE-EXPOSURE PROPHYLAXIS (PREP) TENOFOVIR/LAMIVUDINE/DOLUTEGRAVIR DOLUTEGRAVIR INACTIVATED POLIOVIRUS VACCINE (IPV) (TRANSITION FROM ONE- TO TWO-DOSE) 10- AND 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINES (PCV) (REASSESSMENT)
PROPONENT National AIDS and STI Prevention and Control Program - Philippines (NASPCP) National AIDS and STI Prevention and Control Program - Philippines (NASPCP) National AIDS and STI Prevention and Control Program - Philippines (NASPCP) DOH National Immunization Program DOH National Immunization Program
TOPIC NOMINATION
TOPIC PRIORITIZATION
SCOPING AND PROTOCOL DEVELOPMENT
ASSESSMENT
EVIDENCE APPRAISAL
PRELIMINARY RECOMMENDATION
APPEALS
RESOLUTION
FINAL RECOMMENDATION 17 December 2017 09 August 2021 21 September 2021 13 July 2021 14 August 2020
DECISION OF THE SECRETARY OF HEALTH 18 January 2022 01 September 2021 28 September 2021 10 September 2021 14 August 2020
DISSEMINATION Link to issuanceLink to Evidence SummaryLink to Evidence Summary and IssuanceLink to Evidence Summary and IssuanceLink to issuanceLink to Evidence SummaryLink to IssuanceLink to Evidence Summary
Name of Drug Status
Aflibercept for wet age-related macular degeneration For External Commissioning
Dexamethasone for diabetic macular edema For External Commissioning
Ranibizumab for visual impairment due to macular edema secondary to retinal vein occlusion (branch RVO or central RVO) For External Commissioning
Sitagliptin for Uncontrolled Type 2 Diabetes Mellitus For External Commissioning
TACE with Mitomycin C for patients with non-resectable Hepatocellular Carcinoma For External Commissioning
Insulin aspart (100 U/mL) for Type 1 and Type 2 Diabetes Mellitus For External Commissioning
Insulin glulisine (100 IU/mL, 10 mL vial and 3 mL pre-filled pen) for Type 1 and Type 2 Diabetes Mellitus For External Commissioning
Insulin lispro (Mix - P 814 3ml pre-filled pen (100 U/mL); Insulin Lispro 100 Units/mL, 10 ml vial) For External Commissioning
Pazopanib as treatment for Renal Cell Carcinoma For External Commissioning
Sunitinib for Renal Cell Carcinoma For External Commissioning
Pertuzumab for HER2+ Breast Cancer For finalization of recommendation after appeals
Rituximab SC for Non-Hodgkin’s Lymphoma For finalization of recommendation after appeals
Eribulin for Metastatic Soft Tissue Sarcoma (mSTS) For finalization of recommendation after appeals
Eltrombopag olamine in the treatment of refractory thrombocytopenia among patients with chronic immune thrombocytopenia (ITP) On-going assessment
Abiraterone for adult men with prostate cancer On-going assessment
Dabigatran for myocardial infarction with atrial fibrillation On-going assessment
Dapagliflozin (5mg/10 mg tablet) for adult patients with Type 2 Diabetes Mellitus patients inadequately controlled on metformin monotherapyDapagliflozin On-going assessment
Enzalutamide (40mg soft gel capsule) for adult men with metastatic castration-resistant prostate cancer (mCRPC) On-going assessment
Insulin detemir (100 U/mL) for Type 1 and Type 2 Diabetes Mellitus For finalization of recommendation after appeals
Insulin glargine (100 IU/mL, 10 mL vial and 3 mL pre-filled pen) for Type 1 and Type 2 Diabetes Mellitus For finalization of recommendation after appeals
Rivaroxaban for myocardial infarction with atrial fibrillation On-going assessment
Zoledronic acid for prevention of skeletal-related events in cancer patients On-going assessment
Cerebrolysin for patients with acute ischemic stroke, dementia and traumatic brain injury On-going assessment
Citicoline for acute and recovery phase of cerebral infarction (e.g., ischemia due to stroke) On-going assessment
Nilotinib as first-line treatment for Chronic Phase-Chronic Myeloid Leukemia On-going assessment
Ivabradine for the treatment of stable angina pectoris among adult patients with coronary artery disease On-going assessment
Ticagrelor for the prevention of thrombotic events among patients with Acute Coronary Syndrome On-going assessment
Tirofiban HCl for treatment of unstable angina or non-Q wave myocardial infarction For External Commissioning
PROCESS PEDIA VACCINATION 5 to 11 YRS OLD PEDIA VACCINATION 12 to 17 YRS OLD BOOSTER AND ADDITIONAL DOSE PFIZER ASTRAZENECA SINOVAC SPUTNIK V JOHNSON & JOHNSON MODERNA COVOVAX COVAXIN SINOPHARM
EUA Approval
Data Extraction and Synthesis
HTAC Recommendation
Decision of Secretary of Health
Dissemination Link to Evidence SummaryLink to Evidence SummaryLink to Evidence SummaryVersion 1Version 1Link to Evidence SummaryVersion 1Version 1Link to Evidence SummaryLink to Evidence SummaryLink to Evidence SummaryLink to Evidence Summary
Version 2Version 2Link to Evidence SummaryVersion 2Version 2
Version 3
HEALTH TECHNOLOGY CASIRIVIMAB+INDEVIMAB DEXAMETHASONE FAVIPIRAVIR REMDESIVIR BARICITINIB TOCILUZIMAB
PROPONENT Disease Prevention and Control Bureau (DPCB) Philippine Academy of Ophthalmology DOH Disease Prevention and Control Bureau DOH Disease Prevention and Control Bureau DOH Disease Prevention and Control Bureau DOH Disease Prevention and Control Bureau
TOPIC NOMINATION
TOPIC PRIORITIZATION
ASSESSMENT
RECOMMENDATION
DECISION OF THE SECRETARY OF HEALTH
DISSEMINATION Link to HTAC RecommendationLink to Signed Endorsement Letter and Evidence SummaryDexamethasoneLink to issuanceDexamethasoneLink to issuanceDexamethasoneLink to issuanceDexamethasoneLink to issuance